Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Published:2019-02-01 Issue:2 Volume:5 Page:173
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Aggarwal Charu¹²,Thompson Jeffrey C.³,Black Taylor A.¹,Katz Sharyn I.⁴,Fan Ryan¹,Yee Stephanie S.¹,Chien Austin L.¹,Evans Tracey L.¹²,Bauml Joshua M.¹²,Alley Evan W.¹²,Ciunci Christine A.¹²,Berman Abigail T.¹²,Cohen Roger B.¹²,Lieberman David B.⁵,Majmundar Krishna S.¹,Savitch Samantha L.¹,Morrissette Jennifer J. D.⁵,Hwang Wei-Ting²⁶,Elenitoba-Johnson Kojo S. J.⁵,Langer Corey J.¹²,Carpenter Erica L.¹²

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia

2. Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia

3. Division of Pulmonary, Allergy, and Critical Care Medicine, Thoracic Oncology Group, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia

4. Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia

5. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia

6. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/2/173/17295225/jamaoncology_aggarwal_2018_oi_180083.pdf

Reference33 articles.

1. Cancer treatment and survivorship statistics, 2016.;Miller;CA Cancer J Clin,2016

2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.;Solomon;N Engl J Med,2014

3. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.;Yang;Lancet Oncol,2015

4. Management of non–small-cell lung cancer: recent developments.;Reck;Lancet,2013

5. Targeted therapy for non–small cell lung cancer: current standards and the promise of the future.;Chan;Transl Lung Cancer Res,2015

Cited by 357 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer;Translational Research;2024-10

3. Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC);Clinical Oncology;2024-10

4. Precision oncology: current and future platforms for treatment selection;Trends in Cancer;2024-09

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24